Coral Laboratories reported a 32.20% drop in net profit for FY26 to ₹16.38 crore. Revenue also fell 25.31% to ₹85.90 crore. The company recommended a 20% dividend, subject to shareholder approval.
Coral Laboratories Ltd has announced its financial results for the year ended March 31, 2026, reporting a significant decrease in both revenue and profitability compared to the previous fiscal year. The company's revenue from operations stood at ₹85.90 crore, a 25.31% decline from ₹115.01 crore in FY2025. Net profit for the period also saw a substantial drop of 32.20%, falling to ₹16.38 crore from ₹24.16 crore in the prior year. Basic Earnings Per Share (EPS) declined by 32.18% to ₹45.85 from ₹67.61. Reader Takeaway: Declining revenue and profit pressure; dividend maintained amid performance dip. ## What just happened Coral Laboratories reported audited financial results for the fiscal year 2026. Revenue from operations decreased by 25.31% to ₹85.90 crore, and net profit fell by 32.20% to ₹16.38 crore. The basic EPS also decreased to ₹45.85 from ₹67.61 in the previous year. ## Why this matters The decline in both topline and bottomline performance indicates challenges faced by the company during FY26. Investors will be keen to understand the reasons behind this contraction and the company's strategy to reverse the trend. ## The backstory In the previous fiscal year (FY2025), Coral Laboratories reported revenues of ₹115.01 crore and a net profit of ₹24.16 crore. The company has a history of declaring dividends, and the current recommendation continues this practice despite the lower earnings. ## What changes now The company's board has recommended a final dividend of 20% (₹2.00 per share), which is subject to shareholder approval at the Annual General Meeting. Routine appointments for Internal Auditor (M/s. S K Doshi & Associates) and Cost Auditor (M/s. Aatish Dhatrak & Associates) for FY2027 have also been approved. ## Risks to watch The primary risk for investors is the sustainability of the company's performance. A continued decline in revenue and profit could impact future dividend payouts and shareholder value. The company needs to address the factors causing the performance dip in its formulations segment. ## Peer comparison While specific peer financial data is not provided in the filing, the current results show a downturn for Coral Laboratories. Investors may want to compare its performance with other pharmaceutical companies in the formulations segment to gauge industry-wide trends or specific company challenges. ## Context metrics (time-bound) * **FY2026 Revenue:** ₹85.90 crore (down 25.31% from FY2025) * **FY2026 Profit:** ₹16.38 crore (down 32.20% from FY2025) * **FY2026 Basic EPS:** ₹45.85 (down 32.18% from FY2025) ## What to track next Investors should monitor Coral Laboratories' subsequent quarterly results and management commentary for insights into the reasons for the FY26 performance decline and any strategies implemented to improve sales and profitability. The approval of the recommended dividend will also be a key event for shareholders.
Get stock alerts instantly on WhatsApp
Quarterly results, bulk deals, concall updates and major announcements delivered in real time.
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.
